DE60237597D1 - Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff - Google Patents

Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff

Info

Publication number
DE60237597D1
DE60237597D1 DE60237597T DE60237597T DE60237597D1 DE 60237597 D1 DE60237597 D1 DE 60237597D1 DE 60237597 T DE60237597 T DE 60237597T DE 60237597 T DE60237597 T DE 60237597T DE 60237597 D1 DE60237597 D1 DE 60237597D1
Authority
DE
Germany
Prior art keywords
coenzyme
transmucosal administration
compositions
active substance
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237597T
Other languages
English (en)
Inventor
Kenji Fujii
Taizo Kawabe
Kazunori Hosoe
Takayoshi Hidaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Application granted granted Critical
Publication of DE60237597D1 publication Critical patent/DE60237597D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE60237597T 2001-05-10 2002-05-08 Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff Expired - Lifetime DE60237597D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001139605 2001-05-10
PCT/JP2002/004476 WO2002092067A1 (fr) 2001-05-10 2002-05-08 Composition pour administration transmucosale contenant une coenzyme q en tant qu'ingredient actif

Publications (1)

Publication Number Publication Date
DE60237597D1 true DE60237597D1 (de) 2010-10-21

Family

ID=18986353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237597T Expired - Lifetime DE60237597D1 (de) 2001-05-10 2002-05-08 Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff

Country Status (9)

Country Link
US (1) US7754205B2 (de)
EP (1) EP1388340B1 (de)
KR (2) KR100685696B1 (de)
CN (1) CN100438862C (de)
AT (1) ATE480231T1 (de)
AU (1) AU2002309038B2 (de)
CA (1) CA2443191A1 (de)
DE (1) DE60237597D1 (de)
WO (1) WO2002092067A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3742602B2 (ja) * 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
TWI322008B (en) * 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
US20070243180A1 (en) * 2003-10-31 2007-10-18 Hozumi Tanaka Composition Containing Reduced Coenzyme Q
CN102258503B (zh) 2004-01-22 2019-08-16 迈阿密大学 局部辅酶q10制剂及其使用方法
US20090081683A1 (en) * 2005-11-29 2009-03-26 Genelink, Inc. Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin
JP5103374B2 (ja) * 2006-03-13 2012-12-19 株式会社カネカ 心機能不良改善剤または心機能維持剤
CN101443010A (zh) * 2006-04-10 2009-05-27 三菱瓦斯化学株式会社 脑功能改善剂及含有该改善剂的功能性食品
US10583098B2 (en) * 2006-05-02 2020-03-10 Sung Lan Hsia Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
JP6058263B2 (ja) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー 癌細胞においてアポトーシスを誘導する方法および使用
US20110020312A1 (en) 2009-05-11 2011-01-27 Niven Rajin Narain Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
CN102503798B (zh) * 2011-11-16 2014-07-16 中国农业科学院蜜蜂研究所 一种从蜂花粉中提取辅酶q10的方法及其应用
KR101581508B1 (ko) * 2012-12-03 2015-12-31 가톨릭대학교 산학협력단 코엔자임 ｑ１０을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물
WO2014088301A1 (ko) * 2012-12-03 2014-06-12 가톨릭대학교 산학협력단 코엔자임 ｑ１０을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물
AU2014251045B2 (en) 2013-04-08 2019-06-13 Berg Llc Treatment of cancer using coenzyme Q10 combination therapies
SG11201601583TA (en) 2013-09-04 2016-04-28 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US11419830B2 (en) 2017-05-17 2022-08-23 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
EP1007018B1 (de) * 1997-02-12 2003-10-08 MSE Pharmazeutika GmbH Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19802050A1 (de) 1998-01-21 1999-07-22 Labtec Gmbh Zubereitung zur Freisetzung von Coenzym Q 10 in die Mundhöhle
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6200550B1 (en) 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
DE19905880A1 (de) 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Spray enthaltend Ubichinon Qn
DE19905879A1 (de) 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Ubichinon Qn zur Behandlung von Schmerzen
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
IT1316997B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
US6686485B2 (en) * 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
JP3742602B2 (ja) * 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
US7708990B2 (en) * 2004-03-23 2010-05-04 Kaneka Corporation Coenzyme Q compositions persisting in blood

Also Published As

Publication number Publication date
EP1388340B1 (de) 2010-09-08
CA2443191A1 (en) 2002-11-21
US20040115181A1 (en) 2004-06-17
EP1388340A4 (de) 2004-12-08
US7754205B2 (en) 2010-07-13
KR20060103288A (ko) 2006-09-28
CN100438862C (zh) 2008-12-03
KR20030092082A (ko) 2003-12-03
ATE480231T1 (de) 2010-09-15
AU2002309038B2 (en) 2007-05-17
KR100685696B1 (ko) 2007-02-23
WO2002092067A1 (fr) 2002-11-21
CN1505505A (zh) 2004-06-16
EP1388340A1 (de) 2004-02-11

Similar Documents

Publication Publication Date Title
DE60237597D1 (de) Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff
Shanbhag Oil pulling for maintaining oral hygiene–A review
ATE402692T1 (de) Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
BRPI0507187A (pt) composições para tratamento bucal compreendendo teores biodisponìveis mais altos de compostos antimicrobianos à base de amÈnio quaternário
BRPI0620265B1 (pt) composição oral anti-placa e dessensibilizante
Sterer et al. Oral malodor reduction by a palatal mucoadhesive tablet containing herbal formulation
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
JP2004018470A (ja) 抗菌香料組成物および口臭抑制香料組成物ならびにそれらを含有する口腔用組成物
US20070110683A1 (en) Oral care formulation
DE3774361D1 (de) Verwendung von usninsaeure oder deren derivaten bei der behandlung von zahnfaeule.
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
HUP0303454A2 (hu) 4-Ciano-trifluor-3-(4-fluor-fenil-szulfonil)-2-hidroxi-2-metil-propiono-m-toluididet és pvp-t tartalmazó szilárd gyógyászati készítmény
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
Arweiler et al. Efficacy of an amine fluoride–triclosan mouthrinse as compared to the individual active ingredients
US20240173239A1 (en) Oral Care Additive, Oral Care Composition, Preparation Method, Kit and Uses Thereof
CA2458219A1 (en) Oral rinse for treatment or prevention of bacterial and fungal infection
Lee et al. A randomized, blinded, clinical investigation of breath odor reduction efficacy of a stabilized chlorine-dioxide containing flavored mouthwash
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
PE20040932A1 (es) Metodo de mejora de la circulacion sanguinea
WO2006133412A1 (en) Methods and compositions for the prevention, suppression and elimination of oral pain
Kaur et al. The immediate Term effect of chewing commercially available Meswak (Salvadora persica) on levels of Calcium, Chloride, Phosphate and Thiocyanate in whole saliva
RU2532399C2 (ru) Способ лечения пародонтита
Raj Mohamed et al. Awareness of Therapeutic Benefits of Green Tea among Dental Fraternity
Mani et al. Chlorine dioxide: a potential mouthrinse for oral health
Kashyap et al. Antigingivitis effect of Coenzyme Q10 on plaque induced chronic gingivitis